Incorporating Biosimilars into the Clinical Landscape: Expert Insights for Managed Care Considerations

 A continuing medical education and nursing continuing professional
development activity provided by NAMCP and AAMCN.

This activity is an archive from the live session from the 2023 Fall Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from January 1, 2024 to March 1, 2025

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.


Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This activity is supported by educational grants from
Boehringer Ingelheim and Coherus BioSciences

Biosimilar products are biologic products that are highly similar to already approved biologic drugs developed for various indications. While biosimilars have some differences compared with their reference products, they are mandated to produce identical similarity from their reference biologics in terms of clinical safety and efficacy. As such, these biosimilar products promise to foster unprecedented access to a wide range of life-saving biologics while ensuring a rise in healthcare access and market sustainability.

Biosimilars are expected to have a significant impact on healthcare as they revolutionize the treatments of many disease states. Biosimilars have the potential to reduce healthcare costs and expand patient access to biologic therapies. The high cost of biologic drugs in immunology imposes a substantial burden on the US healthcare system and has created numerous patient access challenges. In recent years, there has been a shift in FDA approvals for biosimilars, with multiple biosimilars for oncology-related supportive care and disease-specific therapeutic indications available on the US market. Healthcare professionals should be appropriately educated about the cost-saving benefits associated with biosimilars. These cost-savings may be significant for patient populations affected by socioeconomic challenges or other healthcare disparities that may limit access to treatment.

Upon completion of this activity, participants will be able to:

  • Discuss the current expert guidelines and recent clinical trial data for available biosimilars and how a customized management plan can improve outcomes

  • Explore the emerging biosimilars based on characteristics that guide selection for patients with immunological conditions

  • Analyze the challenges and barriers that affect the incorporation of biosimilars in clinical practice

  • Utilize shared decision-making and patient-centered factors for initiating and using biosimilars

  • Examine the clinical and managed care considerations for using biosimilars in the current treatment landscape, with a close look at how value-based care can optimize patient outcomes

Allan Gibofsky, MD, JD
Professor of Medicine
Weill Cornell Medicine
Attending Rheumatologist
Co-Director, Clinic for Inflammatory Arthritis
Hospital for Special Surgery

Disclosure Information:
As accredited providers, NAMCP and AAMCN must ensure balance, independence, objectivity, and scientific rigor in all of their activities. All faculty participating in this activity are required to disclose to NAMCP/AAMCN any financial relationships with ineligible companies. NAMCP/AAMCN in turn discloses all relevant financial conflicts to the learners. NAMCP/AAMCN disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All relevant conflicts of interest have been mitigated prior to the commencement of the activity. See below for conflicts of interest.

Disclosures (Relevant Financial Relationships with Ineligible Companies in the Last 24 Months):
Dr. Gibofsky has served as a consultant for AbbVie, Biosplice, Novartis, and Pfizer. He serves as a speaker for AbbVie and Pfizer. He owns stock in AbbVie, Amgen, Horizon Therapeutics, Johnson and Johnson, and Pfizer. All relevant conflicts of interest have been mitigated.

Planning Committee Disclosures (Relevant Financial Relationships with Ineligible Companies in the Last 24 Months):
Bill Williams, MD has no relevant financial relationship with an ineligible company to disclose.
Jeremy Williams has no relevant financial relationship with an ineligible company to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationship with an ineligible company to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in nursing continuing professional development.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

NAMCP and/or this website do not provide medical advice, diagnosis, or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health-related concern, consult with your physician or healthcare professional.This activity is supported by educational grants from
Boehringer Ingelheim and Coherus BioSciences

Click Here To Continue